ELTD1

ELTD1 (EGF, latrophilin and seven transmembrane domain-containing 1), also known as adhesion G protein-coupled receptor L4 (ADGRL4), is a protein that in humans is encoded by the ELTD1 gene. This protein is a member of the adhesion G protein-coupled receptor (aGPCR) family, which plays a role in various biological processes including angiogenesis, cardiovascular development, and cancer progression. ELTD1 has garnered attention for its potential role in the regulation of endothelial cell function and blood vessel formation, making it a target of interest in the study of diseases characterized by abnormal vessel growth such as cancer, cardiovascular diseases, and retinopathy.

Function[edit | edit source]

ELTD1 is involved in the process of angiogenesis, which is the growth of new blood vessels from pre-existing vessels. It is expressed in endothelial cells, where it may influence cell signaling pathways that regulate vascular development and maintenance. The exact mechanisms by which ELTD1 contributes to these processes are still under investigation, but it is believed to play a role in endothelial cell signaling and migration, which are critical steps in angiogenesis.

Clinical Significance[edit | edit source]

The expression of ELTD1 has been found to be upregulated in various types of cancer, suggesting its involvement in tumor angiogenesis and the potential for ELTD1 to serve as a biomarker for cancer progression. Additionally, because of its role in blood vessel formation, ELTD1 is being studied as a potential therapeutic target in diseases where angiogenesis is dysregulated, such as in certain cancers, diabetic retinopathy, and other conditions characterized by excessive or insufficient blood vessel growth.

Research[edit | edit source]

Research on ELTD1 is focused on elucidating its biological functions and its potential as a therapeutic target. Studies have explored its expression in different types of tumors and its impact on tumor growth and metastasis. There is also interest in developing inhibitors of ELTD1 as a means to control angiogenesis in diseases where this process is detrimental.